Invivyd (IVVD) Price & Analysis

Compare

620 Followers

IVVD Stock Chart & Stats

$1.58

-$0.05(-9.00%)

At close: Jan 08 4:00 PM EST

$1.58

-$0.05(-9.00%)

Day’s Range― - ―

52-Week Range$0.35 - $2.74

Previous CloseN/A

Volume606.77K

Average Volume (3M)5.69M

Market Cap

$325.90M

Enterprise ValueN/A

Total Cash (Recent Filing)$84.97M

Total Debt (Recent Filing)$2.68M

Price to Earnings (P/E)―

Beta1.88

Next Earnings

Mar 26, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding214,409,450

10 Day Avg. Volume4,028,033

30 Day Avg. Volume5,691,279

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.78

Price to Sales (P/S)2.07

P/FCF Ratio-0.31

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$10.00

Price Target Upside532.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Pipeline DiversificationPipeline diversification, including candidates for RSV, measles, and Lyme disease, reinforces longer-term growth potential.

Regulatory ApprovalFDA clearance of the investigational new drug application for VYD2311 supports a clear regulatory path for its development as a vaccine-alternative monoclonal antibody for COVID-19 prevention.

Revenue GrowthInvivyd reported revenue growth for PEMGARDA, driven by efforts to increase market awareness and strong uptake among oncologists, rheumatologists, and transplant physicians.

Bears Say

Invivyd News

Invivyd reports Q3 EPS (6c) vs (51c) last year

Reports Q3 revenue $13.129M, consensus $13.1M. “With a strengthened balance sheet and a clear path forward for VYD2311...

2d ago

IVVD

Invivyd price target raised to $10 from $5 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Invivyd (IVVD) to $10 from $5 and...

8d ago

IVVD

Invivyd’s Strategic Advancements and Strong Financial Position Justify Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Invivyd, retaining the price target of $10.00....

1d ago

IVVD

Invivyd Reports Strong Q3 Growth and Strategic Advances

Invivyd ( ($IVVD) ) has released its Q3 earnings. Here is a breakdown of the information Invivyd presented...

2d ago

IVVD

Invivyd’s Earnings Call: Positive Outlook Amid Challenges

Invivyd (($IVVD)) has held its Q3 earnings call. Read on for the main highlights of the call. Invivyd’s...

2d ago

IVVD

Invivyd Reports Strong Q3 Growth and FDA Clearance

An announcement from Invivyd ( ($IVVD) ) is now available. On November 6, 2025, Invivyd reported its third-quarter...

2d ago

IVVD

Invivyd Highlights Antibody Development in New Presentation

Invivyd ( ($IVVD) ) just unveiled an update. On October 30, 2025, Invivyd, Inc. released an investor presentation...

9d ago

IVVD

Invivyd’s VYD2311 Receives FDA Clearance for Trials

Invivyd ( ($IVVD) ) has shared an update. On October 6, 2025, Invivyd, Inc. announced that the U.S....

1M ago

IVVD

Invivyd announces IND clearance, alignment with FDA on VYD2311 program

Invivyd (IVVD) announced that the FDA has cleared the company’s Investigational New Drug application and provided feedback to...

1M ago

IVVD

Invivyd initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Invivyd (IVVD) with an Overweight rating and $10 price target Published first on...

1M ago

IVVD

Invivyd files $350M mixed securities shelf

16:19 EDT Invivyd (IVVD) files $350M mixed securities shelf Published first on TheFly – the ultimate source for...

1M ago

IVVD

Invivyd Appoints New Director Amid Nasdaq Compliance

Invivyd ( ($IVVD) ) has shared an update. On September 22, 2025, Invivyd, Inc. appointed Paul B. Bolno,...

1M ago

IVVD

Invivyd appoints Wave Life Sciences CEO Paul Bolno to board

Invivyd (IVVD) announced the appointment of Paul Bolno to its board of directors and as a member of...

2M ago

WVE

IVVD

Invivyd announces appointment of Kuhl as Chief Communications Officer

Invivyd (IVVD) announced the appointment of Kristie Kuhl as Chief Communications Officer. Kuhl will lead the Company’s communications...

2M ago

IVVD

IVVD FAQ

What was Invivyd’s price range in the past 12 months?

Invivyd lowest stock price was $0.35 and its highest was $2.74 in the past 12 months.

What is Invivyd’s market cap?

Invivyd’s market cap is $325.90M.

When is Invivyd’s upcoming earnings report date?

Invivyd’s upcoming earnings report date is Mar 26, 2026 which is in 137 days.

How were Invivyd’s earnings last quarter?

Invivyd released its earnings results on Nov 06, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.02.

Is Invivyd overvalued?

According to Wall Street analysts Invivyd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Invivyd pay dividends?

Invivyd does not currently pay dividends.

What is Invivyd’s EPS estimate?

Invivyd’s EPS estimate is -0.09.

How many shares outstanding does Invivyd have?

Invivyd has 214,409,450 shares outstanding.

What happened to Invivyd’s price movement after its last earnings report?

Invivyd reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went up 1.316%.

Which hedge fund is a major shareholder of Invivyd?

Currently, no hedge funds are holding shares in IVVD

Invivyd Stock Smart Score

Outperform

Fundamentals

Return on Equity

-67.94%

Trailing 12-Months

Asset Growth

-49.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Invivyd

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Invivyd (IVVD) Earnings & Revenues

Historic Earnings Reports

IVVD Company Deck

IVVD Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant positive developments such as FDA feedback for VYD2311, a successful capital raise, and robust revenue growth. However, challenges related to the lack of modern data on COVID vaccines and logistical coordination with FDA centers were noted.View all IVVD earnings summaries

IVVD Stock 12 Month Forecast

Average Price Target

$10.00

▲(532.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.76,2.393846153846154,3.0276923076923077,3.661538461538462,4.295384615384616,4.929230769230769,5.563076923076923,6.196923076923077,6.8307692307692305,7.464615384615384,8.098461538461539,8.732307692307693,9.366153846153846,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.76,2.393846153846154,3.0276923076923077,3.661538461538462,4.295384615384616,4.929230769230769,5.563076923076923,6.196923076923077,6.8307692307692305,7.464615384615384,8.098461538461539,8.732307692307693,9.366153846153846,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.76,2.393846153846154,3.0276923076923077,3.661538461538462,4.295384615384616,4.929230769230769,5.563076923076923,6.196923076923077,6.8307692307692305,7.464615384615384,8.098461538461539,8.732307692307693,9.366153846153846,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >